Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.8112
+0.00510.63%
Post-market: 0.8000-0.0112-1.38%19:59 EDT
Volume:2.27M
Turnover:1.86M
Market Cap:13.70M
PE:-0.18
High:0.8500
Open:0.8239
Low:0.7800
Close:0.8061
52wk High:12.23
52wk Low:0.7432
Shares:16.89M
Float Shares:9.60M
Volume Ratio:10.14
T/O Rate:23.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-12.57
PE(LYR):-0.04

Loading ...

Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement

Reuters
·
Jun 09

Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 05

Tempest Therapeutics adds Drake Richey, John Yee to board

Reuters
·
Jun 05

Tempest Therapeutics Appoints Drake Richey and John Yee, Md, Mph to Board of Directors

THOMSON REUTERS
·
Jun 05

Tempest Therapeutics issues unregistered warrant for up to 2,344,828 shares in inducement deal

Reuters
·
Jun 02

Tempest Therapeutics director Simantov resigns from board

Reuters
·
May 30

Tempest Therapeutics announces exercise of 1,172,414 warrants at reduced $1.73 per share price

Reuters
·
May 29

Tempest Therapeutics gets Nasdaq notice for failing $2.5 million equity rule

Reuters
·
May 23

Tempest Therapeutics directors Brady, Raab, Pellizzari resign from board

Reuters
·
May 23

Tempest Risk Solutions Appoints David Näslund As CEO

Reuters
·
May 20

Tempest net loss widens 155% to $27.7 million in Q1 2026

Reuters
·
May 15

Tempest Therapeutics Q1 net loss widens on asset acquisition costs

Reuters
·
May 15

Tempest Therapeutics Q1 Operating Income USD -27.719 Million

THOMSON REUTERS
·
May 15

Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 15

Tempest Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 08

Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials

Reuters
·
May 06

Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal

Tempo
·
May 05

Tempest to present TPST-2003 clinical update at ISCT annual meeting

Reuters
·
Apr 29

Tempest Therapeutics provides update on development of TPST-2003

TIPRANKS
·
Apr 22

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

GlobeNewswire
·
Apr 22